Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Toxicon ; 148: 107-122, 2018 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-29704534

RESUMO

Snakebite envenoming represents a major issue in rural areas of tropical and subtropical regions across sub-Saharan Africa, South to Southeast Asia, Latin America and Oceania. Antivenoms constitute the only scientifically validated therapy for snakebite envenomings, provided they are safe, effective, affordable, accessible and administered appropriately. However, the lack of financial incentives in a technology that has remained relatively unchanged for more than a century, has contributed to some manufacturers leaving the market and others downscaling production or increasing the prices, leading to a decline in the availability and accessibility for these life-saving antidotes to millions of rural poor most at risk from snakebites in low income countries. The shortage of antivenoms can be significantly alleviated by optimizing the use of current antivenoms (through the assessment of their specific and paraspecific efficacy against the different medically relevant homologous and heterologous snake venoms) and by generating novel polyspecific antivenoms exhibiting broad clinical spectrum and wide geographic distribution range. Research on venoms has been continuously enhanced by advances in technology. Particularly, the last decade has witnessed the development of omics strategies for unravelling the toxin composition of venoms ("venomics") and to assess the immunorecognition profile of antivenoms ("antivenomics"). Here, we review recent developments and reflect on near future innovations that promise to revolutionize the mutually enlightening relationship between evolutionary and translational venomics.


Assuntos
Antivenenos/farmacologia , Venenos de Serpentes/imunologia , Animais , Avaliação Pré-Clínica de Medicamentos , Proteômica , Venenos de Serpentes/química , Serpentes , Especificidade da Espécie
2.
Toxins (Basel) ; 9(5)2017 05 13.
Artigo em Inglês | MEDLINE | ID: mdl-28505100

RESUMO

Animal-derived antivenoms constitute the mainstay in the therapy of snakebite envenoming. The efficacy of antivenoms to neutralize toxicity of medically-relevant snake venoms has to be demonstrated through meticulous preclinical testing before their introduction into the clinical setting. The gold standard in the preclinical assessment and quality control of antivenoms is the neutralization of venom-induced lethality. In addition, depending on the pathophysiological profile of snake venoms, the neutralization of other toxic activities has to be evaluated, such as hemorrhagic, myotoxic, edema-forming, dermonecrotic, in vitro coagulant, and defibrinogenating effects. There is a need to develop laboratory assays to evaluate neutralization of other relevant venom activities. The concept of the 3Rs (Replacement, Reduction, and Refinement) in Toxinology is of utmost importance, and some advances have been performed in their implementation. A significant leap forward in the study of the immunological reactivity of antivenoms against venoms has been the development of "antivenomics", which brings the analytical power of mass spectrometry to the evaluation of antivenoms. International partnerships are required to assess the preclinical efficacy of antivenoms against snake venoms in different regions of the world in order to have a detailed knowledge on the neutralizing profile of these immunotherapeutics.


Assuntos
Antivenenos/uso terapêutico , Mordeduras de Serpentes/tratamento farmacológico , Venenos de Serpentes/toxicidade , Animais , Antivenenos/farmacologia , Avaliação Pré-Clínica de Medicamentos , Órgãos Governamentais , Humanos , Testes de Neutralização , Proteômica , Proteínas de Répteis/análise , Mordeduras de Serpentes/metabolismo , Venenos de Serpentes/química , Venenos de Serpentes/farmacocinética , Resultado do Tratamento
3.
J Proteomics ; 150: 201-215, 2017 01 06.
Artigo em Inglês | MEDLINE | ID: mdl-27650695

RESUMO

The Papuan black snake (Pseudechis papuanus Serpentes: Elapidae) is endemic to Papua New Guinea, Indonesian Papua and Australia's Torres Strait Islands. We have investigated the biological activity and proteomic composition of its venom. The P. papuanus venom proteome is dominated by a variety (n≥18) of PLA2s, which together account for ~90% of the venom proteins, and a set of low relative abundance proteins, including a short-neurotoxic 3FTx (3.1%), 3-4 PIII-SVMPs (2.8%), 3 cysteine-rich secretory proteins (CRISP; 2.3%) 1-3 l-amino acid oxidase (LAAO) molecules (1.6%). Probing of a P. papuanus cDNA library with specific primers resulted in the elucidation of the full-length nucleotide sequences of six new toxins, including vespryn and NGF not found in the venom proteome, and a calglandulin protein involved in toxin expression with the venom glands. Intravenous injection of P. papuanus venom in mice induced lethality, intravascular haemolysis, pulmonary congestion and oedema, and anticoagulation after intravenous injection, and these effects are mainly due to the action of PLA2s. This study also evaluated the in vivo preclinical efficacy of Australian black snake and polyvalent Seqirus antivenoms. These antivenoms were effective in neutralising the lethal, PLA2 and anticoagulant activities of P. papuanus venom in mice. On the other hand, all of the Seqirus antivenoms tested using an antivenomic approach exhibited strong immunorecognition of all the venom components. These preclinical results suggest that Australian Seqirus1 antivenoms may provide paraspecific protection against P. papuanus venom in humans. SIGNIFICANCE PARAGRAPH: The toxicological profile and proteomic composition of the venom of the Papuan black snake, Pseudechis papuanus, a large diurnal snake endemic to the southern coast of New Guinea and a handful of close offshore islands, were investigated. Intravenous injection of P. papuanus venom in mice induced intravascular hemolysis, pulmonary congestion and edema, anticoagulation, and death. These activities could be assigned to the set of PLA2 molecules, which dominate the P. papuanus venom proteome. This study also showed that Australian Seqirus black snake or polyvalent antivenoms were effective in neutralising the lethal, PLA2 and anticoagulant activities of the venom. These preclinical results support the continued recommendation of these Seqirus antivenoms in the clinical management of P. papuanus envenoming in Australia, Papua New Guinea or Indonesian Papua Province.


Assuntos
Antivenenos , Venenos Elapídicos/análise , Elapidae/metabolismo , Proteoma/análise , Proteômica , Animais , Antivenenos/análise , Antivenenos/metabolismo , Antivenenos/uso terapêutico , Austrália , Avaliação Pré-Clínica de Medicamentos , Venenos Elapídicos/metabolismo , Dose Letal Mediana , Camundongos , Testes de Neutralização , Papua Nova Guiné , Proteoma/metabolismo , Testes de Toxicidade , Resultado do Tratamento
4.
Toxins (Basel) ; 8(10)2016 10 12.
Artigo em Inglês | MEDLINE | ID: mdl-27754342

RESUMO

Snake venom metalloproteinases (SVMPs) play key biological roles in prey immobilization and digestion. The majority of these activities depend on the hydrolysis of relevant protein substrates in the tissues. Hereby, we describe several isoforms and a cDNA clone sequence, corresponding to PII SVMP homologues from the venom of the Central American pit viper Bothriechis lateralis, which have modifications in the residues of the canonical sequence of the zinc-binding motif HEXXHXXGXXH. As a consequence, the proteolytic activity of the isolated proteins was undetectable when tested on azocasein and gelatin. These PII isoforms comprise metalloproteinase and disintegrin domains in the mature protein, thus belonging to the subclass PIIb of SVMPs. PII SVMP homologues were devoid of hemorrhagic and in vitro coagulant activities, effects attributed to the enzymatic activity of SVMPs, but induced a mild edema. One of the isoforms presents the characteristic RGD sequence in the disintegrin domain and inhibits ADP- and collagen-induced platelet aggregation. Catalytically-inactive SVMP homologues may have been hitherto missed in the characterization of snake venoms. The presence of such enzymatically-inactive homologues in snake venoms and their possible toxic and adaptive roles deserve further investigation.


Assuntos
Metaloproteases/isolamento & purificação , Peptídeos/isolamento & purificação , Venenos de Serpentes/química , Viperidae , Adulto , Sequência de Aminoácidos , Animais , Coagulação Sanguínea/efeitos dos fármacos , Caseínas/metabolismo , Clonagem Molecular , DNA Complementar/genética , Edema , Gelatina/metabolismo , Hemorragia , Humanos , Metaloproteases/química , Metaloproteases/genética , Metaloproteases/farmacologia , Camundongos , Modelos Moleculares , Peptídeos/química , Peptídeos/genética , Peptídeos/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Domínios Proteicos , Proteólise , Zinco/metabolismo
5.
Toxicon ; 119: 280-8, 2016 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-27377229

RESUMO

Snakebite envenoming has a heavy burden in the public health in sub-Saharan Africa. The viperid species Echis ocellatus (carpet viper or saw-scaled viper) is the medically most important snake in the savannahs of western sub-Saharan Africa. Several antivenoms are being distributed and used in this region for the treatment of envenomings by E. ocellatus, but the preclinical efficacy of some of these antivenoms has not been assessed. The present study evaluated the preclinical efficacy against E. ocellatus venom of three polyspecific antivenoms: (a) Snake Venom Antiserum (Pan Africa), manufactured by Premium Serums and Vaccines (India); (b) Snake Venom Antiserum (Africa), manufactured by VINS Bioproducts (India); and (c) Antivipmyn(®) Africa, manufactured by Instituto Bioclon (Mexico). Antivenomics analysis revealed the ability of the three antivenoms to immunocapture the majority of components of the venoms of E. ocellatus from Cameroon, Nigeria and Mali, although their maximal immunocapturing capability varied. Bioclon and Premium Serums antivenoms were effective in the neutralization of lethal, hemorrhagic and in vitro coagulant activities of the venom of E. ocellatus from Cameroon, albeit with different potencies. VINS antivenom neutralized hemorrhagic activity of this venom, but failed to neutralize lethality at the highest antivenom dose tested, and had a low neutralizing efficacy against in vitro coagulant effect.


Assuntos
Antivenenos/uso terapêutico , Mordeduras de Serpentes/tratamento farmacológico , Venenos de Víboras/toxicidade , Animais , Avaliação Pré-Clínica de Medicamentos , Camundongos , Viperidae
6.
Toxicon ; 106: 97-107, 2015 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-26415904

RESUMO

Snakebite envenoming causes a heavy toll in sub-Saharan Africa in terms of mortality and sequelae. In the West African savannah, the viperid Echis ocellatus is responsible for the vast majority of bites. In the last decades, several new antivenoms have been introduced for the treatment of these envenomings, although the assessment of their preclinical efficacy against the venom of E. ocellatus has been studied only for some of them. This work analyzed comparatively the ability of four antivenoms (FAV Afrique, EchiTAb G, EchiTAB-Plus-ICP(®), and Inoserp™ Panafricain) to neutralize lethal, hemorrhagic, and in vitro coagulant activities of the venoms of E. ocellatus from Mali, Cameroon, and Nigeria. In addition, an immunoaffinity chromatography antivenomic protocol was used to assess the ability of the four antivenoms to bind to the proteins of these venoms. Results showed that all the antivenoms were effective in the neutralization of the three effects investigated, and were able to immunocapture, completely or partially, the most abundant components in the E. ocellatus venoms from the geographical origins sampled. Our observations also highlighted quantitative differences between antivenoms in their neutralizing and antivenomics profiles, especially regarding neutralization of in vitro coagulant activity, suggesting that different doses of these antivenoms are probably needed for an effective treatment of human envenomings by this species.


Assuntos
Antivenenos/farmacologia , Venenos de Víboras/antagonistas & inibidores , África Subsaariana , Animais , Antivenenos/imunologia , Antivenenos/uso terapêutico , Relação Dose-Resposta a Droga , Avaliação Pré-Clínica de Medicamentos , Humanos , Dose Letal Mediana , Camundongos , Testes de Neutralização , Plasma/efeitos dos fármacos
7.
Toxins (Basel) ; 6(12): 3388-405, 2014 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-25517863

RESUMO

Snakebite envenoming represents a neglected tropical disease that has a heavy public health impact worldwide, mostly affecting poor people involved in agricultural activities in Africa, Asia, Latin America and Oceania. A key issue that complicates the treatment of snakebite envenomings is the poor availability of the only validated treatment for this disease, antivenoms. Antivenoms can be an efficacious treatment for snakebite envenoming, provided they are safe, effective, affordable, accessible and administered appropriately. The shortage of antivenoms in various regions, particularly in Sub-Saharan Africa and some parts of Asia, can be significantly alleviated by optimizing the use of current antivenoms and by the generation of novel polyspecific antivenoms having a wide spectrum of efficacy. Complementing preclinical testing of antivenom efficacy using in vivo and in vitro functional neutralization assays, developments in venomics and antivenomics are likely to revolutionize the design and preclinical assessment of antivenoms by being able to test new antivenom preparations and to predict their paraspecific neutralization to the level of species-specific toxins.


Assuntos
Antivenenos/farmacologia , Avaliação Pré-Clínica de Medicamentos/métodos , África Subsaariana , Animais , Ásia , Proteômica , Mordeduras de Serpentes/terapia , Venenos de Serpentes/química , Serpentes , Especificidade da Espécie
8.
J Proteomics ; 110: 198-208, 2014 Oct 14.
Artigo em Inglês | MEDLINE | ID: mdl-24980637

RESUMO

There is no specific antivenom for the treatment of envenoming by the small-eyed snake, Micropechis ikaheka, a dangerous fossorial species endemic to Papua New Guinea, Irian Jaya (West Papua) and neighbouring islands. This study evaluated one marine (sea snake) and four terrestrial (tiger snake, brown snake, black snake and polyvalent) antivenoms, manufactured in Australia by bioCSL Limited, for their ability to immunoreact ('antivenomic' analysis) and neutralize enzymatic and toxic activities of M. ikaheka venom. All antivenoms neutralized lethality of the venom and attenuated, dose-dependently, myotoxic activity. The polyvalent antivenom also neutralized cardiotoxic activity. In contrast, antivenoms were ineffective in the neutralization of phospholipase A2 (PLA2) and anticoagulant activities. Antivenomics outcomes were in concordance with neutralization tests, for chromatographic peaks corresponding to α-neurotoxins of the three finger family, responsible for lethality, were quantitatively retained in the immunoaffinity columns, whereas peaks corresponding to PLA2s were immunocaptured only to a partial extent. The ability of antivenoms to neutralize lethal, i.e. neurotoxic, and myotoxic activities of M. ikaheka venom, which represent the most relevant clinical manifestations of envenoming, suggests that these antivenoms may provide paraspecific protection in humans, although the poor neutralization of PLA2 supports the need for well-designed clinical studies to not only determine which antivenoms are most appropriate for treatment of M. ikaheka envenoming, but to also fully describe the syndrome of envenoming caused by this beautiful, but lethal species. BIOLOGICAL SIGNIFICANCE: Snakebite by the small-eyed snake, Micropechis ikaheka, in Papua New Guinea can be life-threatening. The predominant clinical features in this envenoming are neurotoxicity and systemic myotoxicity. Although it accounts for only a small proportion of snakebites on the mainland, 40% of snakebites on Karkar Island are attributed to bites by the Ikaheka snake. However, no specific antivenom is available for the treatment of M. ikaheka envenoming in Papua New Guinea. This study evaluated a panel of Australian bioCSL antivenoms for their paraspecific immunoreaction and neutralization of the toxic activities of M. ikaheka venom. All antivenoms exhibited strong immunorecognition of α-neurotoxins of the 3FTx family and neutralized the lethal, i.e. neurotoxic, and myotoxic activities of M. ikaheka venom. However, these antivenoms exhibited poor neutralization of PLA2 and anticoagulant activities. This study suggests that the Australian antivenoms may provide paraspecific protection against M. ikaheka venom in humans, a hypothesis that demands studies aimed at assessing whether these antivenoms neutralize neurotoxicity and myotoxicity in the clinical setting.


Assuntos
Antivenenos/administração & dosagem , Antivenenos/imunologia , Venenos Elapídicos/imunologia , Venenos Elapídicos/intoxicação , Elapidae/metabolismo , Mordeduras de Serpentes/tratamento farmacológico , Mordeduras de Serpentes/imunologia , Animais , Antídotos , Austrália , Avaliação Pré-Clínica de Medicamentos/métodos , Dose Letal Mediana , Masculino , Camundongos , Testes de Neutralização , Ratos , Ratos Sprague-Dawley , Sobrevida
9.
Toxicon ; 64: 60-9, 2013 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-23313380

RESUMO

A polyspecific antivenom is used in Central America for the treatment of envenomings by viperid snakes. This antivenom is generated in horses hyperimmunized with a mixture of venoms from Bothrops asper, Crotalus simus and Lachesis stenophrys. The present study analyzed the ability of this antivenom to neutralize the venoms of three Central American viperid species of the 'Porthidium group', i.e. Porthidium nasutum, Porthidium ophryomegas and Cerrophidion sasai, formerly classified as Cerrophidion godmani. In addition, the immunorecognition of the components of these venoms was assessed by immunoaffinity antivenomics. The antivenom proved effective in neutralizing the lethal, hemorrhagic, myotoxic, phospholipase A(2) (PLA(2)) and proteinase activities of the three venoms, albeit exhibiting quantitative differences in the values of the Median Effective Doses (ED(50)). Excepting for certain low molecular mass bands corresponding to disintegrins, and some PLA(2)s and PI-metalloproteinases, Western blotting and immunoaffinity chromatography revealed immunorecognition of most Porthidium and Cerrophidion venom proteins. In agreement with in vivo neutralization assays, immobilized antivenom IgGs showed higher immunocapturing activity of toxins from both Porthidium taxa than from C. sasai. Overall our results demonstrate a significant paraspecific protection of the Costa Rican polyspecific antivenom against the three venoms sampled. They also stress the need to search for novel ways to enhance the immune response of horses against several weakly immunogenic venom components.


Assuntos
Antivenenos/uso terapêutico , Venenos de Crotalídeos/toxicidade , Viperidae/metabolismo , Animais , Antivenenos/análise , Antivenenos/imunologia , Cromatografia de Afinidade/métodos , Venenos de Crotalídeos/química , Avaliação Pré-Clínica de Medicamentos , Hemorragia/induzido quimicamente , Hemorragia/patologia , Hemorragia/prevenção & controle , Cavalos/imunologia , Injeções Intraperitoneais , Dose Letal Mediana , Longevidade/efeitos dos fármacos , Camundongos , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/patologia , Doenças Musculares/induzido quimicamente , Doenças Musculares/patologia , Doenças Musculares/prevenção & controle , Testes de Neutralização , Inibidores de Fosfolipase A2 , Proteômica/métodos , Mordeduras de Serpentes/tratamento farmacológico , Mordeduras de Serpentes/imunologia , Viperidae/imunologia
10.
Toxicon ; 69: 168-79, 2013 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-23201503

RESUMO

The assessment of the capacity of antivenoms to neutralize the lethal activity of snake venoms is the gold standard in the preclinical analysis of antivenom efficacy, and is routinely performed by manufacturers and quality control laboratories. However, the complexity of snake venom composition and toxicological profile demands that, for many venoms, such as those of viperid snakes and some elapids, the neutralization of lethality be complemented with the analysis of the neutralization of other relevant toxic activities, such as hemorrhagic, myotoxic, necrotizing, procoagulant and defibrinogenating effects. This expanded protocol for preclinical testing of antivenoms should be used when a new antivenom is developed or when an existing antivenom is introduced in a new geographical setting for the neutralization of either homologous or heterologous venoms. In recent years, the assessment of the immunological reactivity of antivenoms has been enriched by the use of proteomic tools, with a methodology named 'antivenomics'. This allows the identification of venom components to which antivenoms have, or lack, antibodies, and thus complements the data gathered in neutralization tests, paving the way for a knowledge-based improvement of antivenom design and efficacy. International projects involving participants of manufacturing, quality control and academic research groups should be promoted in order to gain a deeper understanding on the preclinical neutralizing spectrum of antivenoms.


Assuntos
Antivenenos/farmacologia , Testes de Neutralização , Animais , Anticorpos/sangue , Antivenenos/imunologia , Avaliação Pré-Clínica de Medicamentos , Injeções Intraperitoneais , Dose Letal Mediana , Camundongos , Proteômica , Venenos de Serpentes/toxicidade , Viperidae
11.
J Struct Biol ; 169(2): 226-42, 2010 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-19854274

RESUMO

Royal palm tree peroxidase (RPTP) is a very stable enzyme in regards to acidity, temperature, H(2)O(2), and organic solvents. Thus, RPTP is a promising candidate for developing H(2)O(2)-sensitive biosensors for diverse applications in industry and analytical chemistry. RPTP belongs to the family of class III secretory plant peroxidases, which include horseradish peroxidase isozyme C, soybean and peanut peroxidases. Here we report the X-ray structure of native RPTP isolated from royal palm tree (Roystonea regia) refined to a resolution of 1.85A. RPTP has the same overall folding pattern of the plant peroxidase superfamily, and it contains one heme group and two calcium-binding sites in similar locations. The three-dimensional structure of RPTP was solved for a hydroperoxide complex state, and it revealed a bound 2-(N-morpholino) ethanesulfonic acid molecule (MES) positioned at a putative substrate-binding secondary site. Nine N-glycosylation sites are clearly defined in the RPTP electron-density maps, revealing for the first time conformations of the glycan chains of this highly glycosylated enzyme. Furthermore, statistical coupling analysis (SCA) of the plant peroxidase superfamily was performed. This sequence-based method identified a set of evolutionarily conserved sites that mapped to regions surrounding the heme prosthetic group. The SCA matrix also predicted a set of energetically coupled residues that are involved in the maintenance of the structural folding of plant peroxidases. The combination of crystallographic data and SCA analysis provides information about the key structural elements that could contribute to explaining the unique stability of RPTP.


Assuntos
Araceae/enzimologia , Modelos Moleculares , Peroxidase/química , Conformação Proteica , Sequência de Aminoácidos , Sequência de Bases , Cristalização , Primers do DNA/genética , DNA Complementar/genética , Glicosilação , Cinética , Dados de Sequência Molecular , Peroxidase/genética , Peroxidase/metabolismo , Análise de Sequência de DNA , Espectrometria de Massas em Tandem
12.
FEBS J ; 274(24): 6447-55, 2007 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-18021250

RESUMO

In recent years, heat treatment has been used to prevent the development of chilling injury in fruits and vegetables. The acquired tolerance to chilling seen in treated fruit is related to the accumulation of heat shock proteins (HSPs). The positive effect of heat treatment has generally been verified for only a narrow range of treatment intensities and more reliable methods of determining optimal conditions are therefore needed. In this regard, quantitation of HSPs would seem to be an interesting tool for monitoring purposes. As a step toward the development of analytical methodology, the objective of this study was the isolation and characterization of relevant HSPs from plant tissues. Tomato fruits were exposed to a temperature of 38 degrees C for 0, 3, 20 and 27 h, and protein extracts from pericarp were analysed using SDS/PAGE. Analysis revealed the appearance of an intense 21 kDa protein band in treated samples. IEF of this band showed the presence of four major proteins (HSPC1, HSPC2, HSPC3 and HSPC4) with similar pI values. A monospecific polyclonal antiserum was raised in rabbits against purified HSPC1 protein, which cross-reacted with other small heat shock proteins. The major proteins were characterized by MS/MS analysis of tryptic peptides, all having blocked N-termini. The antiserum obtained proved suitable for detecting increased amounts of small heat shock proteins in tomatoes and grapefruits subjected to heat treatment for 24 and 48 h; these treatments were successful in preventing the development of chilling injury symptoms during cold storage. Our data are valuable for the future development of analytical methods to evaluate the optimal protection induced by heat treatment in different fruits.


Assuntos
Frutas/metabolismo , Proteínas de Choque Térmico Pequenas/metabolismo , Temperatura Alta , Proteínas de Plantas/metabolismo , Solanum lycopersicum/metabolismo , Sequência de Aminoácidos , Eletroforese em Gel de Poliacrilamida , Proteínas de Choque Térmico Pequenas/química , Proteínas de Choque Térmico Pequenas/isolamento & purificação , Immunoblotting , Dados de Sequência Molecular , Proteínas de Plantas/química , Proteínas de Plantas/isolamento & purificação , Isoformas de Proteínas/química , Isoformas de Proteínas/isolamento & purificação , Isoformas de Proteínas/metabolismo , Análise de Sequência de Proteína/métodos , Espectrometria de Massas por Ionização por Electrospray
13.
J Biol Chem ; 280(49): 40714-22, 2005 Dec 09.
Artigo em Inglês | MEDLINE | ID: mdl-16215260

RESUMO

Jerdostatin represents a novel RTS-containing short disintegrin cloned by reverse transcriptase-PCR from the venom gland mRNA of the Chinese Jerdons pit viper Trimeresurus jerdonii. The jerdostatins precursor cDNA contained a 333-bp open reading frame encoding a signal peptide, a pre-peptide, and a 43-amino acid disintegrin domain, whose amino acid sequence displayed 80% identity with that of the KTS-disintegrins obtustatin and viperistatin. The jerdostatin cDNA structure represents the first complete open reading frame of a short disintegrin and points to the emergence of jerdostatin from a short-coding gene. The different residues between jerdostatin and obtustatin/viperistatin are segregated within the integrin-recognition loop and the C-terminal tail. Native jerdostatin (r-jerdostatin-R21) and a R21K mutant (r-jerdostatin-K21) were produced in Escherichia coli. In each case, two conformers were isolated. One-dimensional (1)H NMR showed that conformers 1 and 2 of r-jerdostatin-R21 represent, respectively, well folded and unfolded proteins. The two conformers of the wild-type and the R21K mutant inhibited the adhesion of alpha(1)-K562 cells to collagen IV with IC(50) values of 180 and 703 nm, respectively. The IC(50) values of conformers 2 of r-jerdostatin-R21 and r-jerdostatin-K21 were, respectively, 5.95 and 12.5 microm. Neither r-jerdostatin-R21 nor r-jerdostatin-K21 showed inhibitory activity toward other integrins, including alpha(IIb)beta(3), alpha(v)beta(3), alpha(2)beta(1), alpha(5)beta(1), alpha(4)beta(1), alpha(6)beta(1), and alpha(9)beta(1) up to a concentration of 24 mum. Although the RTS motif appears to be more potent than KTS inhibiting the alpha(1)beta(1) integrin, r-jerdostatin-R21 is less active than the KTS-disintegrins, strongly suggesting that substitutions outside the integrin-binding motif and/or C-terminal proteolytic processing are responsible for the decreased inhibitory activity.


Assuntos
DNA Complementar/genética , Desintegrinas/genética , Integrina alfa1beta1/antagonistas & inibidores , Trimeresurus/metabolismo , Sequência de Aminoácidos , Animais , Sequência de Bases , Clonagem Molecular , Venenos de Crotalídeos , Cisteína/análise , Desintegrinas/química , Desintegrinas/farmacologia , Dissulfetos/análise , Glândulas Exócrinas/química , Expressão Gênica , Espectroscopia de Ressonância Magnética , Modelos Moleculares , Dados de Sequência Molecular , Mutagênese Sítio-Dirigida , Fases de Leitura Aberta , Mapeamento de Peptídeos , Conformação Proteica , Dobramento de Proteína , Proteínas Recombinantes , Tripsina/metabolismo
14.
Yeast ; 21(4): 303-12, 2004 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15042590

RESUMO

Screening of a sugar beet (Beta vulgaris cv. Dita) cDNA library for clones able to confer osmotic tolerance to the osmosensitive gpd1 mutant of Saccharomyces cerevisiae identified a novel serine O-acetyltransferase (BvSAT; EC 2.3.1.30). This enzyme is involved in cysteine biosynthesis in plants and bacteria, producing O-acetylserine, which is converted into cysteine in a reaction catalysed by O-acetylserine sulphydrylase (EC 4.2.99.8). This pathway is not conserved in yeast, where cysteine is synthesized in a four-step pathway starting with homoserine and having O-acetylhomoserine, homocysteine and cystathionine as intermediates. Expression of BvSAT in yeast takes advantage of the activity of yeast O-acetylhomoserine sulphydrylase (MET15/MET17/MET25; EC 4.2.99.10) with O-acetylserine as substrate and induces an alternative cysteine biosynthesis pathway. Our results imply that the resulting increase in cysteine production confers enhanced resistance against osmotic stress in the osmosensitive yeast strain. These data demonstrate that cysteine biosynthesis is a limiting factor in osmotic stress tolerance in yeast.


Assuntos
Acetiltransferases/genética , Beta vulgaris/enzimologia , Cisteína/biossíntese , Saccharomyces cerevisiae/enzimologia , Saccharomyces cerevisiae/genética , Aminoácidos/análise , Sequência de Bases , Primers do DNA , DNA Complementar/genética , Técnicas de Transferência de Genes , Dados de Sequência Molecular , Serina O-Acetiltransferase , Compostos de Sulfidrila/análise
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA